Selenite Treatment Inhibits LAPC-4 Tumor Growth and Prostate-Specific Antigen Secretion in a Xenograft Model of Human Prostate Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 72, Issue 3, 2008, Pages 935-940

  Bhattacharyya, Rumi S ^a   Husbeck, Bryan ^a   Feldman, David ^a   Knox, Susan J ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Androgen independent prostate cancer; LAPC 4 xenograft; Prostate cancer; PSA; Selenite

Indexed keywords

ANTIGENS; ARSENIC COMPOUNDS; BIOLOGICAL MATERIALS; BODY FLUIDS; CELL CULTURE; CHLORINE COMPOUNDS; NONMETALS; ONCOLOGY; PEELING; SELENIUM; SELENIUM COMPOUNDS; VEHICLES;

ANDROGEN RECEPTOR; ANDROGEN-DEPENDENT; ANDROGEN-INDEPENDENT PROSTATE CANCER; CHEMOPREVENTIVE EFFECTS; HUMAN PROSTATE CANCER; IN-VIVO; INTRAPERITONEALLY; LAPC-4 XENOGRAFT; PROSTATE CANCER; PROSTATE-SPECIFIC ANTIGEN; PSA; SELENITE; TUMOR GROWTH; TUMOR VOLUMES; XENOGRAFT MODEL; XENOGRAFT TUMORS;

TUMORS;

ANDROGEN; PROSTATE SPECIFIC ANTIGEN; SELENITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; FEMALE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR VOLUME; TUMOR XENOGRAFT;

ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CELL DIVISION; CELL LINE, TUMOR; FEMALE; HUMANS; MALE; MICE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SODIUM SELENITE; TRANSPLANTATION, HETEROLOGOUS;

EID: 52949111881     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.07.005     Document Type: Article

References (32)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Willett W.C., Polk B.F., Morris J.S., et al. Prediagnostic serum selenium and risk of cancer. Lancet 2 (1983) 130-134
3. Combs Jr. G.F., and Gray W.P. Chemopreventive agents: Selenium. Pharmacol Ther 79 (1998) 179-192
4. Clark L.C., Combs Jr. G.F., Turnbull B.W., et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276 (1996) 1957-1963
5. Duffield-Lillico A.J., Reid M.E., Turnbull B.W., et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: A summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 11 (2002) 630-639
6. Klein E.A. Selenium and vitamin E cancer prevention trial. Ann N Y Acad Sci 1031 (2004) 234-241
7. Stratton M.S., Reid M.E., Schwartzberg G., et al. Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma: Study design and baseline characteristics of the 'Watchful Waiting' Study. Anticancer Drugs 14 (2003) 595-600
8. Waters D.J., Shen S., Cooley D.M., et al. Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate. J Natl Cancer Inst 95 (2003) 237-241
9. Lee S.O., Yeon Chun J., Nadiminty N., et al. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate 66 (2006) 1070-1075
10. Corcoran N.M., Najdovska M., and Costello A.J. Inorganic selenium retards progression of experimental hormone refractory prostate cancer. J Urol 171 (2004) 907-910
11. Diwadkar-Navsariwala V., Prins G.S., Swanson S.M., et al. Selenoprotein deficiency accelerates prostate carcinogenesis in a transgenic model. Proc Natl Acad Sci U S A 103 (2006) 8179-8184
12. Ganther H. Chemical transformations of selenium in living organisms. Improved forms of selenium for cancer prevention. Tetrahedron 53 (1997) 12299-12310
13. Ip C., Thompson H.J., Zhu Z., and Ganther H.E. In vitro and in vivo studies of methylseleninic acid: Evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 60 (2000) 2882-2886
14. Dong Y., Zhang H., Gao A.C., Marshall J.R., and Ip C. Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers. Mol Cancer Ther 4 (2005) 1047-1055
15. Husbeck B., Bhattacharyya R.S., Feldman D., and Knox S.J. Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: Two distinct mechanisms of action. Mol Cancer Ther 5 (2006) 2078-2085
16. Husbeck B., Peehl D.M., and Knox S.J. Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing. Free Radic Biol Med 38 (2005) 50-57
17. Husbeck B., Nonn L., Peehl D.M., and Knox S.J. Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells. Prostate 66 (2006) 218-225
18. Klein K.A., Reiter R.E., Redula J., et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 3 (1997) 402-408
19. Mellinghoff I.K., Vivanco I., Kwon A., Tran C., Wongvipat J., and Sawyers C.L. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6 (2004) 517-527
20. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔ C(T)) method. Methods 25 (2001) 402-408
21. Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 1 (2001) 34-45
22. Koivisto P., Kononen J., Palmberg C., et al. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57 (1997) 314-319
23. Scher H.I., and Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23 (2005) 8253-8261
24. Menter D.G., Sabichi A.L., and Lippman S.M. Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev 9 (2000) 1171-1182
25. Zhong W., and Oberley T.D. Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line. Cancer Res 61 (2001) 7071-7078
26. Zhao R., Xiang N., Domann F.E., and Zhong W. Expression of p53 enhances selenite-induced superoxide production and apoptosis in human prostate cancer cells. Cancer Res 66 (2006) 2296-2304
27. Li G.X., Hu H., Jiang C., Schuster T., and Lu J. Differential involvement of reactive oxygen species in apoptosis induced by two classes of selenium compounds in human prostate cancer cells. Int J Cancer 120 (2007) 2034-2043
28. Li N., Oberley T.D., Oberley L.W., and Zhong W. Overexpression of manganese superoxide dismutase in DU145 human prostate carcinoma cells has multiple effects on cell phenotype. Prostate 35 (1998) 221-233
29. Zhong W., Yan T., Webber M.M., and Oberley T.D. Alteration of cellular phenotype and responses to oxidative stress by manganese superoxide dismutase and a superoxide dismutase mimic in RWPE-2 human prostate adenocarcinoma cells. Antioxid Redox Signal 6 (2004) 513-522
30. Letavayova L., Vlckova V., and Brozmanova J. Selenium: From cancer prevention to DNA damage. Toxicology 227 (2006) 1-14
31. Reid M.E., Stratton M.S., Lillico A.J., et al. A report of high-dose selenium supplementation: Response and toxicities. J Trace Elem Med Biol 18 (2004) 69-74
32. Nilsonne G., Sun X., Nystrom C., et al. Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress. Free Radic Biol Med 41 (2006) 874-885